Kevin Adams, RN, APN Clinical Nurse Specialist - Psych/Mental Health Medicare: Accepting Medicare Assignments Practice Location: 300 Highway 641 N, Camden, TN 38320 Phone: 731-642-0521 Fax: 731-642-1010 |
News Archive
Bristol-Myers Squibb Company and Ambrx, Inc. today announced a collaboration under which Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop and commercialize biologics based on Ambrx's research surrounding the Fibroblast Growth Factor 21 protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure.
Some 90,000 patients per year are treated for Parkinson's disease, a number that is expected to rise by 25 percent annually. Deep Brain Stimulation (DBS), which consists of electrically stimulating the central or peripheral nervous system, is currently standard practice for treating Parkinson's, but it can involve long, expensive surgeries with dramatic side effects. Miniature, ultra-flexible electrodes developed in Switzerland, however, could be the answer to more successful treatment for this and a host of other health issues.
The human body has more than 600 muscles, which enable it to breathe, pump blood, move freely, lift things, and lead an active lifestyle.
Rebiotix Inc. announced today that the U.S. Food and Drug Administration has approved the company's Investigational New Drug application to begin the Phase 2 clinical study of RBX2660 for the treatment of recurrent Clostridium difficile infection.
The University of Pennsylvania's Institute for Regenerative Medicine will host a symposium on Friday, April 11, 2014 to detail the progress researchers are making toward reprogramming human cells to treat a variety of diseases.
› Verified 1 days ago